PMLive6h
AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial
AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...
PMLive6h
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
PMLive6h
Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
PMLive7h
Breaking down the barriers
Not many people would pay for a ticket to a concert where their seat was positioned behind a pillar and directly below the ...